Esperion Therapeutics, Inc. (NASDAQ:ESPR) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have earned an average rating of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year target […]

Leave a Reply

Your email address will not be published.

Previous post Brokerages Set Hiscox Ltd (LON:HSX) PT at GBX 1,228.14
Next post Fuelling The Passion – Classic Car owners defy the Cost-of-Living Crisis